Your browser doesn't support javascript.
loading
COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms.
Malone, Robert W; Tisdall, Philip; Fremont-Smith, Philip; Liu, Yongfeng; Huang, Xi-Ping; White, Kris M; Miorin, Lisa; Del Olmo, Elena Moreno; Alon, Assaf; Delaforge, Elise; Hennecker, Christopher D; Wang, Guanyu; Pottel, Joshua; Smith, Nora; Hall, Julie M; Shapiro, Gideon; Mittermaier, Anthony; Kruse, Andrew C; García-Sastre, Adolfo; Roth, Bryan L; Glasspool-Malone, Jill; Ricke, Darrell O.
Afiliación
  • Malone RW; RW Malone MD LLC, Madison, VA.
  • Tisdall P; Medical School Companion LLC, Marco Island, FL.
  • Fremont-Smith P; MIT Lincoln Laboratory, Lexington, MA.
  • Liu Y; Department of Pharmacology, University of North Carolina, Chapel Hill, Chapel Hill, NC.
  • Huang XP; Department of Pharmacology, University of North Carolina, Chapel Hill, Chapel Hill, NC.
  • White KM; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Miorin L; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Del Olmo EM; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Alon A; Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA.
  • Delaforge E; McGill University, Department of Chemistry, Montreal, Quebec, Canada.
  • Hennecker CD; McGill University, Department of Chemistry, Montreal, Quebec, Canada.
  • Wang G; McGill University, Department of Chemistry, Montreal, Quebec, Canada.
  • Pottel J; Molecular Forecaster Inc, Montreal, Quebec, Canada.
  • Smith N; MIT Lincoln Laboratory, Lexington, MA.
  • Hall JM; Frank H. Netter MD School of Medicine - Quinnipiac University, Hamden, CT.
  • Shapiro G; Pharmorx LLC, Gainesville, FL.
  • Mittermaier A; McGill University, Department of Chemistry, Montreal, Quebec, Canada.
  • Kruse AC; Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA.
  • García-Sastre A; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY,Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, The
  • Roth BL; Department of Pharmacology, University of North Carolina, Chapel Hill, Chapel Hill, NC.
  • Glasspool-Malone J; RW Malone MD LLC, Madison, VA.
  • Ricke DO; MIT Lincoln Laboratory, Lexington, MA.
Res Sq ; 2020 Aug 31.
Article en En | MEDLINE | ID: mdl-32702719
ABSTRACT
SARS-CoV-2 infection is required for COVID-19, but many signs and symptoms of COVID-19 differ from common acute viral diseases. Currently, there are no pre- or post-exposure prophylactic COVID-19 medical countermeasures. Clinical data suggest that famotidine may mitigate COVID-19 disease, but both mechanism of action and rationale for dose selection remain obscure. We explore several plausible avenues of activity including antiviral and host-mediated actions. We propose that the principal famotidine mechanism of action for COVID-19 involves on-target histamine receptor H2 activity, and that development of clinical COVID-19 involves dysfunctional mast cell activation and histamine release.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Res Sq Año: 2020 Tipo del documento: Article País de afiliación: Ciudad del Vaticano
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Res Sq Año: 2020 Tipo del documento: Article País de afiliación: Ciudad del Vaticano